This trial´s aim is to assess if oral prednisone (compared to placebo), administered over five weeks is beneficial in terms of decreased total bilirubin (TBL): reduction of the peak of TBL at least 50% at 14 days or reduction in the time to normalisation of TBL value.
Female and male patients, aged ≥ 18 years.
Patients who have been diagnosed with DILI by the expert committee.
Patients with moderate to severe DILI (elevations of ALT or AST ≥ 5 times the Upper Limit of Normal (ULN) and serum TBL ≥ 2.5 mg/dL).
Patients who do not show a 15% reduction in ALT values or TBL continues to increase 5-10 days after liver damage recognition despite the withdrawal of the culprit drug.
No clear DILI diagnosis after an expert committee DILI assessment.
DILI due to immune-checkpoint inhibitors.
Presence of active infection as evidenced by positive urine or blood culture.
Acute liver failure (international normalized ratio (INR) > 1.5 and hepatic encephalopathy).